Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue The Lancet Neurology Année : 2009

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.

Résumé

High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN-HFS) is the preferred surgical treatment for advanced Parkinson's disease. In the 15 years since its introduction into clinical practice, many studies have reported on its benefits, drawbacks, and insufficiencies. Despite limited evidence-based data, STN-HFS has been shown to be surgically safe, and improvements in dopaminergic drug-sensitive symptoms and reductions in subsequent drug dose and dyskinesias are well documented. However, the procedure is associated with adverse effects, mainly neurocognitive, and with side-effects created by spread of stimulation to surrounding structures, depending on the precise location of electrodes. Quality of life improves substantially, inducing sudden global changes in patients' lives, often requiring societal readaptation. STN-HFS is a powerful method that is currently unchallenged in the management of Parkinson's disease, but its long-term effects must be thoroughly assessed. Further improvements, through basic research and methodological innovations, should make it applicable to earlier stages of the disease and increase its availability to patients in developing countries.

Dates et versions

inserm-00536403 , version 1 (16-11-2010)

Identifiants

Citer

Alim Louis Benabid, Stephan Chabardès, John Mitrofanis, Pierre Pollak. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.. The Lancet Neurology, 2009, 8 (1), pp.67-81. ⟨10.1016/S1474-4422(08)70291-6⟩. ⟨inserm-00536403⟩

Collections

INSERM UGA
64 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More